Bioventus, BCBS of Michigan partner in knee OA initiative — 3 things to know

Bioventus is partnering with Blue Cross Blue Shield of Michigan to provide its knee osteoarthritis treatments to Medicare Advantage and Commercial patients, beginning Jan. 1, 2020.

Advertisement

Three things to know:

1. The arrangement includes Bioventus’ Durolane, Gelsyn-3 and Supartz FX hyaluronic acid-based treatments for knee OA.

2. Durolane is a single-injection, Gelsyn-3 is a three-injection, and Supartz FX is a five-injection joint fluid treatment.

3. Earlier this year Bioventus signed a nationwide contract with UnitedHealthcare to make Durolane and Gelsyn-3 available to employer and individual commercial plans, starting Oct. 1.

More articles on biologics:
Johns Hopkins, Carrum partnership grows to spine surgery
New York spine surgeon sentenced to probation, house arrest — 4 insights
11 PE transactions in orthopedics in 2019

Advertisement

Next Up in Biologics

Advertisement

Comments are closed.